# Sanara MedTech share price today (Sanara MedTech Inc., SMTI)

> Sanara MedTech Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SMTI · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/smti

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $32.17 (+9.8% in a year)
- Revenue (Jun 2026): $28.1 M (+9.0% on a year ago)
- Profit (Jun 2026): −$453 K
- Operating margin: 6.3% (−3.3 points on a year ago)
- ROE: −634%, FY25
- ROIC: 9.3%, against a 10.9% cost of capital: −1.6 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Sanara MedTech share price today? Sanara MedTech Inc.'s share price was $32.17 at the close on 3 November 2026. That is 25.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $17 and $35, and at that close it sat 84% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 2 weeks running. Over the last 1 year the share price moved +11% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Sanara MedTech pay? Sanara MedTech Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Sanara MedTech on? Sanara MedTech is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Sanara MedTech profitable? Sanara MedTech Inc. posted a net loss of $453 K in the Jun 2026 quarter. The full FY25 year was a loss of $37.6 M. That loss is 1.6% of the quarter's revenue. The same quarter a year earlier lost $2.0 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Sanara MedTech make, and is it growing? Sanara MedTech Inc. reported $28.1 M of revenue in the Jun 2026 quarter, +9.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 43.8% a year on average. The last full year, FY25, came in at $103 M. The last four reported quarters add to $110 M. FY25 revenue was $103 M, +19.0% on the year before. Recent pace: the last four quarters grew +13.4% on average, against 43.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +13.0%, against +23.1% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Sanara MedTech keep? Sanara MedTech Inc.'s operating margin was 6.3% in the Jun 2026 quarter, 3.3 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −30.6% and 8.9%. The latest quarter is within that range. Across 5 years it has been between −30.6% and 8.9%, and FY25's 8.9% is the highest of them. Why the margin moved: operating margin changed −3.3 percentage points on the year while gross margin changed +0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Sanara MedTech's profit turning into cash? Sanara MedTech Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $6.8 M of operating cash against −$37.6 M of profit. After $4.6 M of spending on assets, $2.2 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Sanara MedTech's cash go? Sanara MedTech Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.1 M on assets over the last 3 years. Averaged over those years that is 1.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Sanara MedTech's P/E ratio, and how does it compare with its own history? Sanara MedTech Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Sanara MedTech Inc. at 2.9× its FY25 revenue of $103 M. The P/E comes back here once profit turns positive. ## Is the Sanara MedTech business getting better or worse? Sanara MedTech Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Sanara MedTech earn on its capital? Sanara MedTech Inc. earned a ROE of −634% in FY25. Its return on capital used (ROIC) is 1.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −36.4% net margin and 1.41× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −36.4% net margin × 1.41× asset turnover × 12.30× leverage (assets divided by equity) ≈ −631.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.3% − 10.9% = −1.6 percentage points. The 10.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Sanara MedTech have too much debt? Sanara MedTech Inc. has total debt of $48.5 M against shareholder equity of $7.9 M as of Jun 2026, so its debt is 6.12× its equity. Year by year, that ratio went from 0.01 in FY21 to 8.13 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Sanara MedTech shareholding pattern? 10.0% of Sanara MedTech Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Sanara MedTech from balance-sheet trouble? For Sanara MedTech Inc., the Z-score is 3.05. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.05 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Sanara MedTech rank in its industry? There is no score against its industry: Sanara MedTech Inc. is not among the largest members shown in this industry comparison for Medical Instruments & Supplies. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Sanara MedTech compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Sanara MedTech in size? Sanara MedTech is the 34th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Anteris Technologies Global Corp., AngioDynamics, Inc. and Embecta Corp. Just below it: OraSure Technologies, Inc., Utah Medical Products, Inc. and Pro-Dex, Inc. ### Medical Instruments & Supplies companies close in size

1. [Anteris Technologies Global Corp.](https://www.sectoralpha.in/us/stocks/avr) $546 million
2. [AngioDynamics, Inc.](https://www.sectoralpha.in/us/stocks/ango) $493 million
3. [Embecta Corp.](https://www.sectoralpha.in/us/stocks/embc) $344 million
4. Sanara MedTech Inc. $296 million
5. [OraSure Technologies, Inc.](https://www.sectoralpha.in/us/stocks/osur) $243 million
6. [Utah Medical Products, Inc.](https://www.sectoralpha.in/us/stocks/utmd) $222 million
7. [Pro-Dex, Inc.](https://www.sectoralpha.in/us/stocks/pdex) $193 million

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Etoiles Capital Group Co., Ltd](https://www.sectoralpha.in/us/stocks/efty) $302 million · Consulting Services
2. [8x8, Inc.](https://www.sectoralpha.in/us/stocks/eght) $302 million · Software - Application
3. Sanara MedTech Inc. $302 million
4. [Fiverr International Ltd.](https://www.sectoralpha.in/us/stocks/fvrr) $302 million · Internet Content & Information
5. [Prenetics Global Limited](https://www.sectoralpha.in/us/stocks/pre) $301 million · Packaged Foods

## What else do people ask about Sanara MedTech? ### What were Sanara MedTech's latest quarterly results? Sanara MedTech Inc. reported revenue of $28.1 M and a net loss of $453 K for the Jun 2026 quarter. Earnings per share were −$0.05. The operating margin was 6.3%, 3.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Sanara MedTech's market cap? Sanara MedTech Inc.'s market capitalisation is $296 M at a stock price of $32.17. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sanara MedTech performing? Sanara MedTech Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Sanara MedTech's stock price go up? This page does not forecast Sanara MedTech Inc.'s stock price. What it shows instead: the stock price is $32.17. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Sanara MedTech in its business cycle? Sanara MedTech Inc.'s FY25 operating margin was 8.9%, against a 5-year range of −30.6% to 8.9%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 6.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sanara MedTech story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sanara MedTech a stock worth studying right now? What the numbers show: Sanara MedTech Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.